Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results

Abstract

SummaryObjectiveSince 2014, cannabidiol (CBD) has been administered to patients with treatment‐resistant epilepsies (TREs) in an ongoing expanded‐access program (EAP). We report interim results on the safety and efficacy of CBD in EAP patients treated through December 2016.MethodsTwenty‐five US‐based EAP sites enrolling patients with TRE taking stable doses of antiepileptic drugs (AEDs) at baseline were included. During the 4‐week baseline period, parents/caregivers kept diaries of all countable seizure types. Patients received oral CBD starting at 2‐10 mg/kg/d, titrated to a maximum dose of 25‐50 mg/kg/d. Patient visits were every 2‐4 weeks through 16 weeks and every 2‐12 weeks thereafter. Efficacy endpoints included the percentage change from baseline in median monthly convulsive and total seizure frequency, and percentage of patients with ≥50%, ≥75%, and 100% reductions in seizures vs baseline. Data were analyzed descriptively for the efficacy analysis set and using the last‐observation‐carried‐forward method to account for missing data. Adverse events (AEs) were documented at each visit.ResultsOf 607 patients in the safety dataset, 146 (24%) withdrew; the most common reasons were lack of efficacy (89 [15%]) and AEs (32 [5%]). Mean age was 13 years (range, 0.4‐62). Median number of concomitant AEDs was 3 (range, 0‐10). Median CBD dose was 25 mg/kg/d; median treatment duration was 48 weeks. Add‐on CBD reduced median monthly convulsive seizures by 51% and total seizures by 48% at 12 weeks; reductions were similar through 96 weeks. Proportion of patients with ≥50%, ≥75%, and 100% reductions in convulsive seizures were 52%, 31%, and 11%, respectively, at 12 weeks, with similar rates through 96 weeks. CBD was generally well tolerated; most common AEs were diarrhea (29%) and somnolence (22%).SignificanceResults from this ongoing EAP support previous observational and clinical trial data showing that add‐on CBD may be an efficacious long‐term treatment option for TRE.

A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects

“…In vitro studies and an in vivo generalized seizure model showed that cannabidiol reduced seizure severity, and in recent phase 3 trials, cannabidiol at doses up to 20 mg/kg/day was effective in reducing the frequency of treatment‐resistant seizures in patients with DS (where the target patient population included only pediatric patients) and LGS (where the target patient population included both pediatric and adult patients) . These data are supported by results published from a multisite open‐label expanded access program of cannabidiol, first in 214 pediatric and adult patients with treatment‐resistant epilepsies, and most recently in 607 patients …”

The pharmacological management of Lennox-Gastaut syndrome and critical literature review

“…Cannabidiol (CBD) is an unconventional compound which exerts antiepileptic properties through a novel multiple mechanism of action. In recent years, CBD has been used, in experimental way and at different dosages in children and adults, to treat several drug-resistant epilepsies, including LGS, with promising results in terms of long-term seizure frequency reduction and safety [85]. The efficacy and safety of CBD as add-on anticonvulsant therapy for patients with LGS has been assessed in two phase III placebo-controlled RCTs [86,87]; the former [86] involved 171 individuals with refractory seizures from 24 different clinical sites, who were randomly assigned to receive 20 mg/kg oral CBD daily or placebo during a 14-week treatment period.…”

Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial

“…In 214 pediatric patients with childhood‐onset treatment‐resistant epilepsy (20% of whom had DS) treated with GW Pharmaceuticals' formulation of CBD in physician‐initiated expanded‐access programs, add‐on CBD reduced seizure frequency with an acceptable safety profile, with a second, recently completed analysis extending the findings through 96 weeks in 607 patients . A 14‐week, double‐blind, placebo‐controlled trial (GWPCARE1 Part B) in patients with DS demonstrated a significant reduction in convulsive seizure frequency with CBD vs placebo, with higher rates of adverse events (AEs; including somnolence and diarrhea) and reversible liver enzyme elevations …”